Sirolimus (Rapamycin)

Also known as: Hyftor (0.2% topical gel brand), Rapamune, Rapamune (oral brand), mTOR inhibitor, rapamycin

DermatologyOtherWellness

In plain English

Sirolimus (rapamycin) is an FDA-approved medicine used to prevent organ-transplant rejection and to treat certain conditions. Because it blocks a cellular growth pathway (mTOR) tied to aging, it is being explored off-label at low, intermittent doses for longevity and healthy aging. Human anti-aging evidence is still preliminary. It suppresses the immune system and can affect blood sugar, cholesterol, and wound healing, so it requires careful medical oversight.

The science

Sirolimus inhibits the mechanistic target of rapamycin (mTOR), a nutrient-sensing kinase central to cell growth and autophagy. In a landmark study, rapamycin extended median and maximal lifespan in genetically heterogeneous mice even when started late in life (Harrison et al., Nature 2009), the first pharmacologic lifespan extension in a mammal, catalyzing interest in geroscience. It is FDA-approved for transplant immunosuppression and lymphangioleiomyomatosis. Longevity/healthspan use in humans is off-label and supported mainly by animal data and small early human studies; immunosuppression, dyslipidemia, hyperglycemia, mouth ulcers, and impaired wound healing are recognized risks.

References

• Harrison DE et al., Nature 2009
• Wataya-Kaneda M et al., sirolimus gel vs placebo for facial angiofibromas in TSC (RCT), JAMA Dermatol 2018
• Mannick JB & Lamming DW, targeting the biology of aging with mTOR inhibitors, Nat Aging 2023
• Nicholson-Cole R et al., targeting ageing with rapamycin in humans (systematic review), Lancet Healthy Longev 2024